Single Tablet Per Day for HIV Project

In August 2006, Gilead and MSD announced an agreement for the distribution of Atripla in 106 developing countries around the world where convenient treatment options are critical to patient compliance and adherence to therapy.

Single Tablet per Day: Atripla Fixed-Dose Combination

This program increases access to Atripla®, the first once-daily single tablet regimen for the treatment of HIV infection in adults. It is a fixed-dose combination of the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz, and the nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir disoproxil fumarate.

Partnership objectives:

  • Reduce impact on the disease in resource-limited settings by using combinations of different ARVs to treat people living with HIV/AIDS.
  • Reduce the risk of people living with HIV/AIDS developing resistance.


  • Bristol-Myers Squibb

    Service Providers
    Staff size: 10,000+

    Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail against serious diseases. Around the...

  • Management Sciences for Development (MSD)

    Development Consulting
    United States | Staff size: Unknown

    Management Sciences for Development (MSD) is an international development consulting firm committed to help build strong justice sectors to support a culture of respect for the rule of...

  • Gilead

    Goods Supplier
    United States | Staff size: 501-1000

    Gilead Sciences was founded in 1987 in Foster City, California. In 25 years, Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio, growing pipeline of...

More Resources

Key Information

  • Start Date 2006